Axim Biotechnologies, Inc. SEC filings AXIM

Axim Biotechnologies, Inc. has 306 filings in SEC EDGAR's recent list, going back to Mar 10, 2011. Its latest annual report, Form 10-K, was filed on Apr 16, 2024 for the period ended Dec 31, 2023. The latest quarterly report (Form 10-Q) was filed on Aug 19, 2024, covering the quarter ended Jun 30, 2024. The most recent current report (Form 8-K) was filed on Oct 15, 2024 (change in control, officer or director change). The company's fiscal year ends on December 31.

Form Description Filed Period
10-Q Quarterly report Aug 19, 2024 Jun 30, 2024
10-Q/A Amended quarterly report May 22, 2024 Mar 31, 2024
10-Q Quarterly report May 20, 2024 Mar 31, 2024
10-Q Quarterly report Nov 20, 2023 Sep 30, 2023
10-Q Quarterly report Aug 21, 2023 Jun 30, 2023
10-Q Quarterly report May 22, 2023 Mar 31, 2023
10-Q/A Amended quarterly report Nov 15, 2022 Sep 30, 2022
10-Q Quarterly report Nov 14, 2022 Sep 30, 2022
10-Q Quarterly report Aug 16, 2022 Jun 30, 2022
10-Q Quarterly report May 23, 2022 Mar 31, 2022
10-Q Quarterly report Nov 22, 2021 Sep 30, 2021
10-Q Quarterly report Aug 23, 2021 Jun 30, 2021
10-Q/A Amended quarterly report Jun 2, 2021 Mar 31, 2021
10-Q Quarterly report May 24, 2021 Mar 31, 2021
10-Q/A Amended quarterly report Nov 27, 2020 Sep 30, 2020
10-Q Quarterly report Nov 20, 2020 Sep 30, 2020
10-Q/A Amended quarterly report Aug 18, 2020 Jun 30, 2020
10-Q Quarterly report Aug 14, 2020 Jun 30, 2020
10-Q/A Amended quarterly report Jul 2, 2020 Mar 31, 2020
10-Q Quarterly report Jun 29, 2020 Mar 31, 2020
10-Q Quarterly report Nov 14, 2019 Sep 30, 2019
10-Q Quarterly report Aug 14, 2019 Jun 30, 2019
10-Q Quarterly report May 15, 2019 Mar 31, 2019
10-Q Quarterly report Nov 14, 2018 Sep 30, 2018
10-Q/A Amended quarterly report Aug 17, 2018 Jun 30, 2018
10-Q Quarterly report Aug 14, 2018 Jun 30, 2018
10-Q/A Amended quarterly report May 18, 2018 Mar 31, 2018
10-Q Quarterly report May 15, 2018 Mar 31, 2018
10-Q Quarterly report Nov 20, 2017 Sep 30, 2017
10-Q/A Amended quarterly report Sep 14, 2017 Jun 30, 2017
10-Q/A Amended quarterly report Sep 14, 2017 Mar 31, 2017
10-Q Quarterly report Aug 21, 2017 Jun 30, 2017
10-Q Quarterly report May 22, 2017 Mar 31, 2017
10-Q/A Amended quarterly report Nov 30, 2016 Sep 30, 2016
10-Q Quarterly report Nov 21, 2016 Sep 30, 2016
10-Q/A Amended quarterly report Aug 25, 2016 Jun 30, 2016
10-Q Quarterly report Aug 22, 2016 Jun 30, 2016
10-Q/A Amended quarterly report May 26, 2016 Mar 31, 2016
10-Q Quarterly report May 23, 2016 Mar 31, 2016
10-Q Quarterly report Nov 23, 2015 Sep 30, 2015
10-Q/A Amended quarterly report Aug 27, 2015 Jun 30, 2015
10-Q Quarterly report Aug 19, 2015 Jun 30, 2015
10-Q Quarterly report May 13, 2015 Mar 31, 2015
10-Q Quarterly report Nov 14, 2014 Sep 30, 2014
10-Q/A Amended quarterly report Aug 26, 2014 Jun 30, 2014
10-Q Quarterly report Aug 19, 2014 Jun 30, 2014
10-Q/A Amended quarterly report Jun 18, 2014 Mar 31, 2014
10-Q Quarterly report May 20, 2014 Mar 31, 2014
10-Q Quarterly report Nov 18, 2013 Sep 30, 2013
10-Q Quarterly report Aug 14, 2013 Jun 30, 2013
10-Q Quarterly report May 15, 2013 Mar 31, 2013
10-Q Quarterly report Nov 19, 2012 Sep 30, 2012
10-Q Quarterly report Aug 14, 2012 Jun 30, 2012
10-Q Quarterly report May 17, 2012 Mar 31, 2012
10-Q/A Amended quarterly report Nov 21, 2011 Sep 30, 2011
10-Q Quarterly report Nov 17, 2011 Sep 30, 2011

Showing 56 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
AXIM (OTC)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
San Diego, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1514946
Former names
AXIM INTERNATIONAL INC. (until Aug 13, 2014)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.